Cynapsus Therapeutics Company Profile (CVE:CTH)

About Cynapsus Therapeutics (CVE:CTH)

Cynapsus Therapeutics logoCynapsus Therapeutics Inc. is a specialty pharmaceutical company developing non-injectable delivery of apomorphine to be used as a rescue therapy for off motor symptoms of Parkinson's disease. The Company's drug candidate, APL-130277, is a fast-acting reformulation of apomorphine, which is approved in an injection formulation to rescue patients from off episodes. APL-130277 is a bilayer film that incorporates a neutralizing agent. The Company is focused on clinical development and maximizing the commercialization potential of APL-130277, primarily through a semi-virtual outsourcing business model integrating a team of formulation developers, active pharmaceutical ingredient (API) suppliers, regulatory and intellectual property experts, neuroscientists and central nervous system researchers.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: CVE:CTH
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 52 Week Range: C$14.00 - C$53.67
  • Trailing P/E Ratio:
  • P/E Growth:
Frequently Asked Questions for Cynapsus Therapeutics (CVE:CTH)

What is Cynapsus Therapeutics' stock symbol?

Cynapsus Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "CTH."

Who are some of Cynapsus Therapeutics' key competitors?

How do I buy Cynapsus Therapeutics stock?

Shares of Cynapsus Therapeutics and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Cynapsus Therapeutics' stock price today?

One share of Cynapsus Therapeutics stock can currently be purchased for approximately C$53.50.

MarketBeat Community Rating for Cynapsus Therapeutics (CVE CTH)
Community Ranking:  4.2 out of 5 (   )
Outperform Votes:  11 (Vote Outperform)
Underperform Votes:  2 (Vote Underperform)
Total Votes:  13
MarketBeat's community ratings are surveys of what our community members think about Cynapsus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cynapsus Therapeutics (CVE:CTH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cynapsus Therapeutics (CVE:CTH)
No equities research coverage for this company has been tracked by


Earnings History for Cynapsus Therapeutics (CVE:CTH)
Earnings by Quarter for Cynapsus Therapeutics (CVE:CTH)
Earnings History by Quarter for Cynapsus Therapeutics (CVE CTH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/14/2014($0.02)($0.04)ViewN/AView Earnings Details
5/9/2014($0.04)($0.03)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cynapsus Therapeutics (CVE:CTH)
Current Year EPS Consensus Estimate: $-3.17 EPS


Dividend History for Cynapsus Therapeutics (CVE:CTH)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Cynapsus Therapeutics (CVE:CTH)
No insider trades for this company have been tracked by


Headline Trends for Cynapsus Therapeutics (CVE:CTH)
Latest Headlines for Cynapsus Therapeutics (CVE:CTH)
No headlines for this company have been tracked by



Cynapsus Therapeutics (CTH) Chart for Thursday, July, 27, 2017

This page was last updated on 7/27/2017 by Staff